JP2006526628A5 - - Google Patents

Download PDF

Info

Publication number
JP2006526628A5
JP2006526628A5 JP2006513093A JP2006513093A JP2006526628A5 JP 2006526628 A5 JP2006526628 A5 JP 2006526628A5 JP 2006513093 A JP2006513093 A JP 2006513093A JP 2006513093 A JP2006513093 A JP 2006513093A JP 2006526628 A5 JP2006526628 A5 JP 2006526628A5
Authority
JP
Japan
Prior art keywords
seq
peptide
composition
epitopes
ctl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006513093A
Other languages
English (en)
Japanese (ja)
Other versions
JP5156882B2 (ja
JP2006526628A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/011895 external-priority patent/WO2004094454A2/en
Publication of JP2006526628A publication Critical patent/JP2006526628A/ja
Publication of JP2006526628A5 publication Critical patent/JP2006526628A5/ja
Application granted granted Critical
Publication of JP5156882B2 publication Critical patent/JP5156882B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006513093A 2003-04-18 2004-04-16 Ｈｌａ−ａ２腫瘍関連抗原ペプチドおよび組成物 Expired - Fee Related JP5156882B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46372403P 2003-04-18 2003-04-18
US60/463,724 2003-04-18
PCT/US2004/011895 WO2004094454A2 (en) 2003-04-18 2004-04-16 Hla-a2 tumor associated antigen peptides and compositions

Publications (3)

Publication Number Publication Date
JP2006526628A JP2006526628A (ja) 2006-11-24
JP2006526628A5 true JP2006526628A5 (https=) 2007-06-07
JP5156882B2 JP5156882B2 (ja) 2013-03-06

Family

ID=33310811

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006513093A Expired - Fee Related JP5156882B2 (ja) 2003-04-18 2004-04-16 Ｈｌａ−ａ２腫瘍関連抗原ペプチドおよび組成物

Country Status (12)

Country Link
US (5) US20080274129A1 (https=)
EP (1) EP1620456B1 (https=)
JP (1) JP5156882B2 (https=)
AU (2) AU2004232971A1 (https=)
CA (1) CA2522812C (https=)
CY (1) CY1115311T1 (https=)
DK (1) DK1620456T3 (https=)
ES (1) ES2456666T3 (https=)
PL (1) PL1620456T3 (https=)
PT (1) PT1620456E (https=)
SI (1) SI1620456T1 (https=)
WO (1) WO2004094454A2 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340577B2 (en) * 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US20070098776A1 (en) * 1999-12-13 2007-05-03 Fikes John D HLA class I A2 tumor associated antigen peptides and vaccine compositions
EP2292642A1 (en) * 2003-06-10 2011-03-09 Opal Therapeutics Pty Ltd Immunomodulating compositions, uses therefor and processes for their production
US7612162B2 (en) 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
CN101687022B (zh) * 2007-03-26 2016-09-07 莱顿大学医学中心附属莱顿教学医院 Prame衍生的肽以及包括该肽的免疫原组合物
CN106310293A (zh) 2007-09-27 2017-01-11 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
JP2011502484A (ja) 2007-11-01 2011-01-27 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Ｈｌａ−ｄｒ結合性ペプチドおよびそれらの使用
WO2009146523A1 (en) 2008-06-05 2009-12-10 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
EP2569633B1 (en) * 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
CA2809362C (en) * 2010-08-24 2020-03-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Educatn Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
MY166516A (en) 2010-12-02 2018-07-05 Oncotherapy Science Inc Tomm34 peptides and vaccines including the same
CN113876945A (zh) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
US20150359864A1 (en) * 2012-03-09 2015-12-17 Oncotherapy Science, Inc. Pharmaceutical composition containing peptides
PL2826856T3 (pl) * 2013-07-16 2016-06-30 Sia Latima Genetycznie stabilny onkolityczny wirus RNA, sposób jego wytwarzania i zastosowanie
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
JP6474893B2 (ja) * 2014-11-06 2019-02-27 オーエスイー・イミュノセラピューティクス 脳転移の処置のための治療用マルチペプチドｔ特異的免疫療法
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
IL255722B2 (en) 2015-06-29 2024-05-01 Ose Immunotherapeutics A method for inducing an early memory response with an anticancer vaccine of short peptides
PT3359183T (pt) * 2015-10-06 2020-08-13 Invectys Construções de poliepítopo para utilização em imunoterapia
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
PL4029494T3 (pl) * 2017-01-25 2026-03-23 Ose Immunotherapeutics Sposób wytwarzania stabilnej emulsji do dostarczania peptydów
NZ765655A (en) 2017-11-27 2026-01-30 Ose Immunotherapeutics Improved treatment of cancer
US20200179500A1 (en) 2018-12-05 2020-06-11 Wayne State University Methods and immunogenic compositions relating to her2 with selective sequence modifications
AU2020340983A1 (en) 2019-09-04 2022-03-10 The Board Of Trustees Of The Leland Stanford Junior University Cross-reactive epitope for multiple sclerosis
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
CN115772227A (zh) * 2021-09-08 2023-03-10 珠海市丽珠单抗生物技术有限公司 新型冠状病毒SARS-CoV-2的Delta变异株疫苗与应用
WO2025093541A1 (en) 2023-10-31 2025-05-08 Ose Immunotherapeutics Combination of interleukin 7 and tumour associated antigen vaccine

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US6267965B1 (en) 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5270202A (en) * 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5679640A (en) 1991-02-12 1997-10-21 Cytel Corporation Immunosuppressant peptides
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
WO1994003205A1 (en) 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
BR9406652A (pt) 1993-03-05 1996-09-10 Cytel Corp Composição
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
EP0726941B1 (en) * 1993-08-06 2002-04-03 Epimmune Inc. Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl
DE69435171D1 (de) 1993-09-14 2009-01-08 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
US6660276B1 (en) 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
WO1996018409A1 (en) 1994-12-14 1996-06-20 The Scripps Research Institute In vivo activation of tumor-specific cytotoxic t cells
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
PT876398E (pt) 1996-01-24 2002-12-31 Epimmune Inc Inducao de respostas imunitarias contra determinantes desejados
US5951975A (en) * 1996-06-28 1999-09-14 University Of Pittsburgh Induction of CTLs specific for natural antigens by cross priming immunization
US6180398B1 (en) 1996-07-12 2001-01-30 Virogeneitics Corporation Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation
CA2278189A1 (en) 1997-01-31 1998-08-06 Epimmune, Inc. Peptides and peptide-loaded antigen presenting cells for the activation of ctl
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US6432707B1 (en) * 1997-12-24 2002-08-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
FR2788449B1 (fr) 1999-01-14 2001-02-16 Oreal Nanoemulsion a base de citrates d'alkylether, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
ATE512666T1 (de) * 1999-06-29 2011-07-15 Epimmune Inc Hla-bindende peptide und ihre verwendungen
EP1235848A4 (en) 1999-12-10 2005-02-09 Epimmune Inc INDUCING CELLULAR IMMUNE RESPONSES TO CARCINOEMBRYONIC ANTIGEN USING PEPTIDE AND NUCLEIC ACID-CONTAINING COMPOSITIONS
CA2393662A1 (en) 1999-12-10 2001-06-14 Epimmune Inc. Inducing cellular immune responses to p53 using peptide and nucleic acid compositions
EP1239866A4 (en) 1999-12-10 2005-02-09 Epimmune Inc INDUCTION OF HER2 / NEU CELLULAR IMMUNE RESPONSES USING PEPTIDE AND NUCLEIC ACID-CONTAINING COMPOSITIONS
JP2003516344A (ja) * 1999-12-13 2003-05-13 エピミューン， インコーポレイテッド Ｈｌａクラスｉａ２腫瘍関連抗原ペプチドおよびワクチン組成物
US6602510B1 (en) * 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
US20030224036A1 (en) * 1999-12-13 2003-12-04 Fikes John D Hla class I a2 tumor associated antigen peptides and vaccine compositions
US20070098776A1 (en) * 1999-12-13 2007-05-03 Fikes John D HLA class I A2 tumor associated antigen peptides and vaccine compositions
JP2003521245A (ja) 1999-12-21 2003-07-15 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、前立腺癌抗原に対する細胞性免疫応答の誘導
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
EP1305414A2 (en) * 2000-07-31 2003-05-02 Aventis Pasteur Limited Modified cea and uses thereof

Similar Documents

Publication Publication Date Title
JP2006526628A5 (https=)
US6602510B1 (en) HLA class I A2 tumor associated antigen peptides and vaccine compositions
EP1620456B1 (en) Hla-a2 tumor associated antigen peptides and compositions
JP4776131B2 (ja) ヘテロクリティックアナログおよび関連方法
CA2932798C (en) Formulations for neoplasia vaccines
US20110318408A1 (en) Hla class i a2 tumor associated antigen peptides and vaccine compositions
TWI504407B (zh) 癌疫苗組合物
KR101391561B1 (ko) Ｈｌａ-ａ*3303 구속성 ｗｔ1 펩티드, 및 그것을 포함하는 의약 조성물
WO2001041741A9 (en) Hla class i a2 tumor associated antigen peptides and vaccine compositions
JP2019510465A (ja) 乳がんおよびその他のがんに対する免疫療法において使用するためのペプチドおよびペプチドの組み合わせ
TW201209410A (en) Methods for the diagnosis and treatment of cancer based on AVL9
US20060018915A1 (en) Heteroclitic analogs and related methods
US20140147490A1 (en) Hla class i a2 tumor associated antigen peptides and vaccine compositions
US8871902B2 (en) Immunogenic POTE peptides and methods of use
HK40091839A (zh) 用於治疗癌症的方法和组合物
HK40090579A (zh) 用於治疗癌症的方法和组合物